SCHEMBL5569720

SCHEMBL5569720

O=C(Nc1ccc(Oc2ccncc2)cc1)Nc1ccc(OC2CCNCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 9/20 0.50
▸ CSF1R P07333 2/20 0.48
▸ FLT3 P36888 2/20 0.48
▸ BRAF P15056 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ TNNI3K Q59H18 1/20 0.48
▸ RIPK2 O43353 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ MAPK13 O15264 1/20 0.46
▸ IKBKB O14920 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569087 0.86 RORC (0.51) RAF1CSF1RFLT3BRAFKDR
SCHEMBL5569222 0.83 KDR (0.53) RAF1CSF1RFLT3BRAFKDR
SCHEMBL5565626 0.82 RAF1 (0.63) RAF1CSF1RFLT3BRAFKDR
SCHEMBL187501 0.79 HRH1 (0.66) KCNH2IKBKB
Hydrochloric Acid SCHEMBL2877569 0.78 HRH1 (0.63) KCNH2IKBKB
Hydrochloric Acid SCHEMBL639360 0.78 HRH1 (0.63) KCNH2IKBKB
SCHEMBL943416 0.77 KCNH2 (0.52) CSF1RFLT3KCNH2MEN1LMNA
SCHEMBL5569557 0.76 RAF1 (0.61) RAF1CSF1RFLT3BRAFKDR
SCHEMBL1870322 0.76 NPC1 (0.57) FLT3KCNH2KDM4EPOLBRAB9A
SCHEMBL19707994 0.75 EPHX2 (0.53) RAB9AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A — — 2007-07-19 — — JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 — — EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 — — WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 — — EP disclosed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS RAF1 2/4885CSF1R 2346/4885FLT3 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback